



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




DZD9008

Item No. 38900

CAS Registry No.: 2370013-49-1
Formal Name: N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-2-propenamide

MF: C₂₉H₃₅ClFN₇O₃
FW: 584.1
Purity: ≥95%
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DZD9008 is supplied as a solid. A stock solution may be made by dissolving the DZD9008 in the solvent of choice, which should be purged with an inert gas. DZD9008 is soluble in acetonitrile.

Description

DZD9008 is an irreversible inhibitor of EGFR containing a lysine-to-arginine mutation at position 858 and T790M (EGFR^{L858R,T790M}; IC₅₀ = 1.1 nM).¹ It is selective for EGFR^{L858R,T790M} over Bruton's tyrosine kinase (BTK), wild-type EGFR, focal adhesion kinase (FAK), HER2, and HER4 (IC₅₀s = 213, 226, 255, 392, and 704 nM, respectively) but also inhibits wild-type EGFR containing an exon 19 deletion, EGFR^{T790M} containing an exon 19 deletion, EGFR^{L585R}, EGFR^{G192A}, and EGFR^{L861Q} (IC₅₀s = 1.3-12 nM). DZD9008 (25 and 50 mg/kg twice per day) reduces tumor volume in a patient-derived xenograft (PDX) mouse model of non-small cell lung cancer (NSCLC).

Reference

1. Wang, M., Yang, J.C., Mitchell, P.L., *et al.* Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations. *Cancer Discov.* **12**(7), 1676-1689 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM